Pharmacological characterization of Sch527123, a potent allosteric CXCR1/CXCR2 antagonist

Journal of Pharmacology and Experimental Therapeutics

Volumn 322, Issue 2, 2007, Pages 477-485

  Gonsiorek, Waldemar ^a   Fan, Xuedong ^a   Hesk, David ^a   Fossetta, James ^a   Qiu, Hongchen ^a   Jakway, James ^a   Billah, Motasim ^a   Dwyer, Michael ^a   Chao, Jianhua ^a   Deno, Gregory ^a   Taveras, Art ^a   Lundell, Daniel J ^a   Hipkin, R William ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXY N,N DIMETHYL 3 [2 [[1 (5 METHYLFURAN 2 YL)PROPYL]AMINO] 3,4 DIOXOCYCLOBUT 1 ENYLAMINO]BENZAMIDE; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CXCR 1 RECEPTOR ANTAGONIST; FORMYLMETHIONYLLEUCYLPHENYLALANINE; MYELOPEROXIDASE; SCH 527123; UNCLASSIFIED DRUG;

ALLOSTERISM; ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG INHIBITION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG SPECIFICITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; RECEPTOR INTRINSIC ACTIVITY;

ANIMALS; BENZAMIDES; BINDING, COMPETITIVE; CALCIUM SIGNALING; CELL LINE; CELL MEMBRANE; CHEMOTAXIS; COMPLEMENT C5A; CYCLOBUTANES; DOSE-RESPONSE RELATIONSHIP, DRUG; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); HUMANS; INTERLEUKIN-8; MICE; MOLECULAR STRUCTURE; N-FORMYLMETHIONINE LEUCYL-PHENYLALANINE; NEUTROPHILS; PROTEIN BINDING; RADIOLIGAND ASSAY; RECEPTORS, INTERLEUKIN-8A; RECEPTORS, INTERLEUKIN-8B; SIGNAL TRANSDUCTION;

EID: 34547114011     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.118927     Document Type: Article

References (34)

1. Ahuja SK, Lee JC, and Murphy PM (1996) CXC chemokines bind to unique sets of selectivity determinants that can function independently and are broadly distributed on multiple domains of human interleukin-8 receptor B. Determinants of high affinity binding and receptor activation are distinct. J Biol Chem 271:225-232.
2. Baggiolini M and Walz A (1989) [Naf/nap-1, a new peptide which activates neutrophil leukocytes]. Schweiz Med Wochenschr 119:1285-1289.
3. Banks C, Bateman A, Payne R, Johnson P, and Sheron N (2003) Chemokine expression in IBD. Mucosal chemokine expression is unselectively increased in both ulcerative colitis and Crohn's disease. J Pathol 199:28-35.
4. Beeh KM, Kornmann O, Buhl R, Culpitt SV, Giembycz MA, and Barnes PJ (2003) Neutrophil chemotactic activity of sputum from patients with COPD: role of interleukin 8 and leukotriene B4. Chest 123:1240-1247.
5. Bertini R, Allegretti M, Bizzarri C, Moriconi A, Locati M, Zampella G, Cervellera MN, Di Cioccio V, Cesta MC, Galliera E, et al. (2004) Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury. Proc Natl Acad Sci U S A 101:11791-11796.
6. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
7. Chapman RW, Minnicozzi M, Celly CS, Phillips JE, King TT, Hipkin RW, Fan X, Rindgen D, Deno G, Bond R, et al. (2007) A novel, orally active CXCR1/2 receptor antagonist, Sch527123, inhibits neutrophil recruitment, mucus production, and goblet cell hyperplasmia in animal models of pulmonary inflammation. J Pharmocol Exp Ther 322:486-493.
8. 50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
9. Christophers E, Schroder JM, and Mrowietz U (1989) Identification of two endogenous neutrophil-activating peptides in psoriatic skin and inflammatory cells: C5ades arg and NAP. Dermatologica 179:9-15.
10. Cox MA, Jenh CH, Gonsiorek W, Fine J, Narula SK, Zavodny PJ, and Hipkin RW (2001) Human interferon-inducible 10-kDa protein and human interferon-inducible T cell alpha chemoattractant are allotopic ligands for human CXCR3: differential binding to receptor states. Mol Pharmacol 59:707-715.
11. De Boer WI (2002) Cytokines and therapy in COPD: a promising combination? Chest 121:209S-218S.
12. Dwyer MP, Yu Y, Chao J, Aki C, Chao J, Biju P, Girijavallabhan V, Rindgen D, Bond R, Mayer-Ezel R, et al. (2006) Discovery of 2-hydroxy-N,N- dimethyl-3-{2-[[(R)-1-(5-methylfuran-2-yl)propyl]amino]-3, 4-dioxocyclobut-1-enylamino}benzamide (SCH 527123): a potent, orally bioavailable CXCR2/CXCR1 receptor antagonist. J Med Chem DOI: 10.1021/jm0609622.
13. Feniger-Barish R, Yron I, Meshel T, Matityahu E, and Ben-Baruch A (2003) IL-8-induced migratory responses through CXCR1 and CXCR2: association with phosphorylation and cellular redistribution of focal adhesion kinase. Biochemistry 42:2874-2886.
14. 35S]GTPγS exchange assays in cell membranes and permeabilized peripheral blood lymphocytes. J Immunol Methods 273:15-27.
15. Hay DW and Sarau HM (2001) Interleukin-8 receptor antagonists in pulmonary diseases. Curr Opin Pharmacol 1:242-247.
16. Hipkin RW, Deno G, Fine J, Sun Y, Wilburn B, Fan X, Gonsiorek W, and Wiekowski MT (2004) Cloning and pharmacological characterization of CXCR1 and CXCR2 from Macaca fascicularis. J Pharmacol Exp Ther 310:291-300.
17. Hipkin RW, Friedman J, Clark RB, Eppler CM, and Schonbrunn A (1997) Agonist-induced desensitization, internalization, and phosphorylation of the sst2A somatostatin receptor. J Biol Chem 272:13869-13876.
18. Kenakin T (1997) Affinity, in Pharmacologic Analysis of Drug-Receptor Interaction, pp 242-288, Lippincott-Raven Publishers, Philadelphia-New York.
19. Kulke R, Bornscheuer E, Schluter C, Bartels J, Rowert J, Sticherling M, and Christophers E (1998) The CXC receptor 2 is overexpressed in psoriatic epidermis. J Invest Dermatol 110:90-94.
20. Kurdowska A, Noble JM, Grant IS, Robertson CR, Haslett C, and Donnelly SC (2002) Anti-interleukin-8 autoantibodies in patients at risk for acute respiratory distress syndrome. Crit Care Med 30:2335-2337.
21. Maeda K, Nakata H, Koh Y, Miyakawa T, Ogata H, Takaoka Y, Shibayama S, Sagawa K, Fukushima D, Moravek J, et al. (2004) Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro. J Virol 78:8654-8662.
22. Mukaida N (2003) Pathophysiological roles of interleukin-8/CXCL8 in pulmonary diseases. Am J Physiol 284:L566-L577.
23. Nickoloff BJ, Karabin GD, Barker JN, Griffiths CE, Sarma V, Mitra RS, Elder JT, Kunkel SL, and Dixit VM (1991) Cellular localization of interleukin-8 and its inducer, tumor necrosis factor-alpha in psoriasis. Am J Pathol 138:129-140.
24. Patel L, Charlton SJ, Chambers JK, and Macphee CH (2001) Expression and functional analysis of chemokine receptors in human peripheral blood leukocyte populations. Cytokine 14:27-36.
25. Schulz BS, Michel G, Wagner S, Suss R, Beetz A, Peter RU, Kemeny L, and Ruzicka T (1993) Increased expression of epidermal IL-8 receptor in psoriasis. Down-regulation by FK-506 in vitro. J Immunol 151:4399-4406.
26. Suetomi K, Lu Z, Heck T, Wood TG, Prusak DJ, Dunn KJ, and Navarro J (1999) Differential mechanisms of recognition and activation of interleukin-8 receptor subtypes. J Biol Chem 274:11768-11772.
27. Takashima K, Miyake H, Kanzaki N, Tagawa Y, Wang X, Sugihara Y, Iizawa Y, and Baba M (2005) Highly potent inhibition of human immunodeficiency virus type 1 replication by TAK-220, an orally bioavailable small-molecule CCR5 antagonist. Antimicrob Agents Chemother 49:3474-3482.
28. Thatcher TH, McHugh NA, Egan RW, Chapman RW, Hey JA, Turner CK, Redonnet MR, Seweryniak KE, Sime PJ, and Phipps RP (2005) Role of CXCR2 in cigarette smoke-induced lung inflammation. Am J Physiol 289:L322-L328.
29. Traves SL, Smith SJ, Barnes PJ, and Donnelly LE (2004) Specific CXC but not CC chemokines cause elevated monocyte migration in COPD: a role for CXCR2. J Leukoc Biol 76:441-450.
30. Watson C, Jenkinson S, Kazmierski W, and Kenakin T (2005) The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor. Mol Pharmacol 67:1268-1282.
31. White JR, Lee JM, Young PR, Hertzberg RP, Jurewicz AJ, Chaikin MA, Widdowson K, Foley JJ, Martin LD, Griswold DE, et al. (1998) Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration. J Biol Chem 273:10095-10098.
32. Wolf M, Delgado MB, Jones SA, Dewald B, Clark-Lewis I, and Baggiolini M (1998) Granulocyte chemotactic protein 2 acts via both IL-8 receptors, CXCR1 and CXCR2. Eur J Immunol 28:164-170.
33. Woods JM, Katschke KJ, Jr., Tokuhira M, Kurata H, Arai KI, Campbell PL, and Koch AE (2000) Reduction of inflammatory cytokines and prostaglandin E2 byIL-13 gene therapy in rheumatoid arthritis synovium. J Immunol 165:2755-2763.
34. Wu L, Ruffing N, Shi X, Newman W, Soler D, Mackay CR, and Qin S (1996) Discrete steps in binding and signaling of interleukin-8 with its receptor. J Biol Chem 271:31202-31209.